Abstract
This retrospective study has revealed that human cadaveric renal grafts preserved with hypertonic citrate solution have a significantly higher proportion with primary graft function compared with EuroCollins preserved grafts. Furthermore, Hypertonic citrate-preserved grafts have better early renal function. Those grafts with primary function show an improved graft survival at 12 months when compared with those grafts which had delayed function. There was no difference in renal graft function at 6 months following transplantation between the hypertonic citrate and EuroCollins-preserved grafts nor in the graft losses from rejection. Although the overall graft failure rate in the hypertonic citrate group is higher, this is due to patient mortality and not to rejection.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
